Cargando…

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature

INTRODUCTION: Pheochromocytomas and sympathetic paragangliomas (PPGL) are neuroendocrine catecholamine-secreting tumors that are usually localized. Metastatic disease is rare and systemic treatment consists of conventional chemotherapy and high-specific-activity iodine-131-MIBG which was approved by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Economides, Minas P., Shah, Amishi Y., Jimenez, Camilo, Habra, Mouhammed A., Desai, Monica, Campbell, Matthew T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731902/ https://www.ncbi.nlm.nih.gov/pubmed/33329398 http://dx.doi.org/10.3389/fendo.2020.594264

Ejemplares similares

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas
por: Jimenez, Camilo, et al.
Publicado: (2020)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
por: Jimenez, Camilo
Publicado: (2018)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

The use of temozolomide in paediatric metastatic phaeochromocytoma/paraganglioma: A case report and literature review
por: Urquhart, Calum, et al.
Publicado: (2022)

Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
por: Alshamsan, Bader, et al.
Publicado: (2020)

The prevalence and spectrum of reported incidental adrenal abnormalities in abdominal computed tomography of cancer patients: The experience of a comprehensive cancer center
por: Qdaisat, Aiham, et al.
Publicado: (2022)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients
por: Buti, Sebastiano, et al.
Publicado: (2022)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

Temozolomide Is a Potential Therapeutic Tool for Patients With Metastatic Pheochromocytoma/Paraganglioma—Case Report and Review of the Literature
por: Tong, Anli, et al.
Publicado: (2020)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

Glucose Intolerance on Phaeochromocytoma and Paraganglioma—The Current Understanding and Clinical Perspectives
por: Abe, Ichiro, et al.
Publicado: (2020)

Preoperative Management of Pheochromocytoma and Paraganglioma
por: Fang, Fang, et al.
Publicado: (2020)

Tumour microenvironment in pheochromocytoma and paraganglioma
por: Martinelli, Serena, et al.
Publicado: (2023)

Pheochromocytoma/paraganglioma-associated cardiomyopathy
por: Szatko, Alicja, et al.
Publicado: (2023)

Is Gangliocytic Paraganglioma Designated as a Subtype of Composite Paragangliomas and Originated From Pancreas Islet? A Case Report and Review of Literature
por: Li, Jing, et al.
Publicado: (2022)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Pheochromocytomas and Paragangliomas: Clinical and Genetic Approaches
por: Costa, Marcia Helena Soares, et al.
Publicado: (2015)

Pheochromocytomas and Paragangliomas as Causes of Endocrine Hypertension
por: Canu, Letizia, et al.
Publicado: (2019)

Cancer Stem Cells in Pheochromocytoma and Paraganglioma
por: Scriba, Laura D., et al.
Publicado: (2020)

Editorial: Predictive tools in pheochromocytoma and paraganglioma
por: Ceccato, Filippo, et al.
Publicado: (2023)

A case of cabozantinib therapy leading to complete remission for massive intra-intestinal bleeding and worsening metastatic sites following nivolumab and ipilimumab therapy
por: Ishida, Kyohei, et al.
Publicado: (2023)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study
por: Shawa, Hassan, et al.
Publicado: (2013)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study
por: Ma, Xiaosen, et al.
Publicado: (2020)

SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis
por: Su, Tingwei, et al.
Publicado: (2023)

Cabozantinib for progressive metastatic medullary thyroid cancer: a review
por: Colombo, Joshua R, et al.
Publicado: (2014)

The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
por: Peng, Song, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_iaeck9o2ff5rp2segor316t5p2